Literature DB >> 7138746

The binding of prednisolone in human serum and to recrystallized human albumin in vitro.

W H Steele, G M Hawksworth, H E Barber.   

Abstract

1 Prednisolone binding in human serum and to recrystallized human serum albumin was measured by continuous ultrafiltration. 2 At serum concentrations of prednisolone up to 0.6 micron, 95.0% was bound but at higher concentrations the binding became non-linear falling to 80.5% at 1.8 microns. At even higher concentrations binding in serum became linear again and paralleled the binding to albumin which was linear throughout the entire range of prednisolone concentrations. 3 A binding model was proposed which included a saturable component attributable to binding to transcortin and a non-saturable binding to albumin. 4 Computer simulations using the experimentally determined binding parameters of the model indicated that binding in serum was critically dependent on transcortin concentration and almost independent of albumin concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7138746      PMCID: PMC1427477          DOI: 10.1111/j.1365-2125.1982.tb04954.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

3.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

4.  Plasma protein binding of prednisolone in normal volunteers and arthritic patients.

Authors:  I T Ağabeyoğlu; R F Bergstrom; W R Gillespie; J G Wagner; D R Kay
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

5.  Nomogram for prednisone-prednisolone adjustment dose in patients with hypoalbuminemia.

Authors:  F Centeno; G Robles; M Uribe; S G Lozada; G I Suárez
Journal:  Rev Invest Clin       Date:  1978 Jan-Mar       Impact factor: 1.451

6.  Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients.

Authors:  M B Ray; V J Desmet; A F Bradburne; J Desmyter; J Fevery; J De Groote
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

7.  Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.

Authors:  L W Powell; E Axelsen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

8.  Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.

Authors:  S W Schalm; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

9.  Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man.

Authors:  A Angeli; R Frajria; R De Paoli; D Fonzo; F Ceresa
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

10.  Plasma protein-binding parameters of prednisolone in immune disease patients receiving long-term prednisone therapy.

Authors:  J G Wagner; D Wexler; I T Ağabeyoğlu; R F Bergstrom; E Sakmar; D R Kay
Journal:  J Lab Clin Med       Date:  1981-04
  10 in total
  6 in total

1.  Prediction of drug distribution into human milk from physicochemical characteristics.

Authors:  H C Atkinson; E J Begg
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Pharmacokinetics of prednisolone in children with nephrosis.

Authors:  P F Miller; C J Bowmer; J Wheeldon; J T Brocklebank
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

3.  Prediction of drug concentrations in human skim milk from plasma protein binding and acid-base characteristics.

Authors:  H C Atkinson; E J Begg
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

4.  Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.

Authors:  A J Taggart; C Astbury; J S Dixon; H A Bird
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

5.  Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.

Authors:  G Gatti; E Perucca; G M Frigo; L D Notarangelo; L Barberis; A Martini
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

6.  Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers.

Authors:  Tafsir Bashar; Mohd Nazmul Hasan Apu; Md Shaki Mostaid; Md Saiful Islam; Abul Hasnat
Journal:  Dose Response       Date:  2018-07-25       Impact factor: 2.658

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.